| Is the St. George’s respiratory questionnaire an appropriate measure of symptom severity and activity limitations for clinical trials in COPD? Analysis of pooled data from five … A Loubert, A Regnault, J Meunier, FS Gutzwiller, SA Regnier International Journal of Chronic Obstructive Pulmonary Disease, 2103-2113, 2020 | 11 | 2020 |
| DREAMM-2: single-agent belantamab mafodotin (Belamaf) effects on patient-reported outcome (PRO) measures in patients with relapsed/refractory multiple myeloma (RRMM) R Popat, S Lonial, PM Voorhees, S Degli Esposti, I Gupta, J Opalinska, ... Blood 136, 27-28, 2020 | 7 | 2020 |
| Evaluating the impact of calibration of patient-reported outcomes measures on results from randomized clinical trials: a simulation study based on Rasch measurement theory A Loubert, A Regnault, V Sébille, JB Hardouin BMC medical research methodology 22 (1), 224, 2022 | 5 | 2022 |
| A toolbox of different approaches to analyze and present PRO-CTCAE data in oncology studies A Regnault, A Loubert, B Gorsh, R Davis, A Cardellino, K Creel, S Quéré, ... JNCI: Journal of the National Cancer Institute 115 (5), 586-596, 2023 | 3 | 2023 |
| PCN309 Methodology for Evaluating Meaningful Change Thresholds in Patient-Reported Outcome (PRO) Measures for Corneal Events in Patients With Relapsed/Refractory Multiple … L Eliason, A Loubert, B Gorsh, J Meunier, D Kleinman, S Sapra, ... Value in Health 23, S477, 2020 | 3 | 2020 |
| Establishing clinically meaningful within-individual improvement thresholds for eight patient-reported outcome measures in people with relapsing-remitting multiple sclerosis N Greene, S Quéré, DP Bury, F Mazerolle, M M’Hari, A Loubert, ... Journal of Patient-Reported Outcomes 7 (1), 61, 2023 | 2 | 2023 |
| Landscape review of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in oncology: Adoption and recent learnings. A Regnault, S Quéré, B Gorsh, S Sapra, A Loubert, R Davis, L Nelsen, ... Journal of Clinical Oncology 39 (15_suppl), e18587-e18587, 2021 | 2 | 2021 |
| P1112: PATIENT-REPORTED OUTCOMES (PRO) AMONG PATIENTS WITH MANTLE CELL LYMPHOMA RECEIVING PIRTOBRUTINIB AFTER PRIOR COVALENT BTKI: INTERIM PRO ANALYSIS FROM THE BRUIN PHASE 1/2 … J Cohen, L Roeker, C Cheah, T Eyre, K Patel, J Woyach, J Seymour, ... HemaSphere 7 (S3), e34270c5, 2023 | 1 | 2023 |
| Contemplating clinical trials as measurement systems: A new perspective for measurement uncertainty associated with treatment benefit demonstration A Loubert, A Regnault, V Sebille, JB Hardouin, J Melin, S Cano, ... QUALITY OF LIFE RESEARCH 29 (SUPPL 1), S25-S25, 2020 | 1 | 2020 |
| Patient-Reported Outcomes (PROs) Among Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving Pirtobrutinib: Analysis from … CC Coombs, JA Woyach, JR Brown, P Ghia, LE Roeker, K Patel, TA Eyre, ... Blood 142, 6535, 2023 | | 2023 |
| P-252 Impact of belantamab mafodotin vs pomalidomide/low-dose dexamethasone treatment on health-related quality of life and vision-related functioning in patients with relapsed … M Dimopoulos, K Weisel, V Hungria, S Sapra, N Sule, M Li, A McKeown, ... Clinical Lymphoma Myeloma and Leukemia 23, S174-S175, 2023 | | 2023 |
| Does the Multiple Sclerosis Impact Scale-29 (MSIS-29) have the range to capture the experience of fully ambulatory multiple sclerosis patients? Learnings from the ASCLEPIOS studies A Regnault, A Loubert, R Brennan, J Meunier, C Naujoks, S Cano, ... Multiple Sclerosis Journal–Experimental, Translational and Clinical 9 (3 …, 2023 | | 2023 |
| CO115 Psychometric Evaluation of Customized Lymphoma-Specific Symptom Measures Using the EORTC QLQ-C30 and Item Library: Data from a Phase 1/2 Clinical Trial of Pirtobrutinib A Loubert, K Creel, L Hess, A Regnault, N Payakachat Value in Health 26 (6), S36, 2023 | | 2023 |
| Application de la théorie de mesure de Rasch à la recherche clinique: implications pratiques et théoriques d’une démarche métrologique de l’évaluation des critères de jugement … A Loubert Nantes Université, 2022 | | 2022 |
| Evaluation of the Impact of Calibration of Patient-Reported Outcomes Measures on Clinical Trial Results: A Simulation Study based on Rasch Measurement Theory A Loubert, A Regnault, V Sébille, JB Hardouin | | 2021 |
| Statistical analysis of symptomatic adverse events over the course of oncology clinical trials: What are the appropriate methods for longitudinal PRO-CTCAE data? A Regnault, A Loubert, R Davis, B Gorsh, S Quere, L Nelsen, L Eliason QUALITY OF LIFE RESEARCH 30 (SUPPL 1), S123-S124, 2021 | | 2021 |
| Should we calibrate PRO instruments in clinical trials? A comprehensive simulation study based on Rasch Measurement Theory A Loubert, A Regnault, V Sebille, S Cano, JB Hardouin QUALITY OF LIFE RESEARCH 29 (SUPPL 1), S166-S166, 2020 | | 2020 |
| Doit-on étalonner les instruments PRO dans les essais cliniques? Résultat d’une étude de simulation dans le cadre de la théorie de la mesure de Rasch A Loubert, A Regnault, V Sebille, S Cano, J Hardouin Revue d'Épidémiologie et de Santé Publique 68, S103-S104, 2020 | | 2020 |
| PSS20 CONFIRMATION OF THE MEASUREMENT PROPERTIES OF THE NATIONAL EYE INSTITUTE VISUAL FUNCTIONING QUESTIONNAIRE 28 ITEM RASCH-BASED SCORING IN NEOVASCULAR AGE-RELATED MACULAR … A Skelly, A Loubert, P Goswami, J Meunier, A Regnault Value in Health 22, S889-S890, 2019 | | 2019 |
| Calibrating Rasch measures for assessing treatment effects in a clinical trial setting: findings from a simulation study A Loubert, A Regnault, V Sebille, S Cano, JB Hardouin QUALITY OF LIFE RESEARCH 28, S113-S113, 2019 | | 2019 |
